Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTATM) and cisplatin: A multicenter phase II trial |
| |
Authors: | C. Manegold U. Gatzemeier J. von Pawel R. Pirker R. Malayeri J. Blatter K. Krejcy |
| |
Affiliation: | (1) Thoraxklinik Heidelberg GmBH, Germany;(2) Krankenhaus Großhansdorf, Großhansdorf, Germany;(3) Asklepios Fachklinik Munchen-Gauting, Germany;(4) University of Vienna, Austria;(5) Lilly Deutschland GmbH, Bad Homburg, Germany;(6) Eli Lilly Regional Operations GmBH, Vienna, Austria |
| |
Abstract: | Background:To evaluate the activity of MTA plus cisplatin inchemotherapy-naïve patients with non-small cell lung cancer (NSCLC).Patients and methods:Thirty-six chemotherapy-naïve patientswith NSCLC received 500 mg/m2 MTA plus 75 mg/m2cisplatin every 21 days, with 4 mg dexamethasone orally twice daily on the daybefore, of, and after MTA administration.Results:Median age was 58 years. WHO performance status was0–2. Eighteen patients each had stage IIIB and IV disease. Seventeenpatients each had squamous-cell and adenocarcinoma; two had undifferentiateddisease. Fourteen patients (39%; 95% confidence interval:23%–57%) showed partial response; seventeen (47%)had stable disease. Median survival was 10.9 months. Twenty-one patients(59%) experienced grade 3 or 4 granulocytopenia without fever orinfection. Five (14%) and six (17%) patients experienced grade3 anemia and grade 3 or 4 thrombocytopenia, respectively. Nonhematologicaltoxicities included grade 3 nausea in two patients (6%), and grade 3and 4 diarrhea in one patient (3%) each. One patient each experiencedgrade 4 ALT and grade 3 bilirubin and AST elevations.Conclusions:MTA plus cisplatin is well tolerated and activeagainst NSCLC. Further studies of this combination are warranted. |
| |
Keywords: | cisplatin MTA non-small-cell lung cancer (NSCLC) phase II |
本文献已被 Oxford SpringerLink 等数据库收录! |
|